US state seeks lowest prices from drugmakers

18 January 2001

US state governor Bill Janklow of South Dakota has asked his statelegislature to approve a bill that would require pharmaceutical companies to give all hospitals, pharmacies and retailers operating in the state the lowest price offered there. While drug companies could still offer discounts for high-volume purchases, these low rates could not be made available to only one group of buyers, reports the Associated Press.

Senator Tim Johnson, who represents South Dakota, applauded the governor's action and noted that the proposal is similar to a bill he has presented to the Congress. Implementing price-control legislation state-by-state might be difficult, he told the AP, but it could prod the federal government to act.

While a spokesman for the Pharmaceutical Research and Manufacturers of America told the Marketletter that his organization now wants to look at the details of the governor's proposal, a PhRMA spokesman earlier told the press service that the plan might not be the best move for patients. Competitive discounts mean more patients are getting lower prices on prescription drugs, he said, and Gov Janklow's proposal tinkers with the competitive private marketplace, "which is a bad idea."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight